Literature DB >> 18473847

Advanced glycation end products (AGEs) and their involvement in liver disease.

Hideyuki Hyogo1, Sho-ichi Yamagishi.   

Abstract

Advanced glycation end products (AGEs) are a heterogeneous group of molecules, formed in vivo both by non-oxidative and oxidative reactions of sugars and their adducts to proteins and lipids. It is now well established that formation and accumulation of AGEs progress during normal aging, and at an extremely accelerated rate under diabetes, thus being implicated in various types of AGEs-related disorders such as diabetic vascular complications, neurodegenerative diseases and cancers. There is a growing body of evidence that activation of RAGE (receptor for AGEs) system is also implicated in these devastating disorders. Indeed, the engagement of RAGE with AGEs is shown to elicit oxidative stress generation and subsequently evoke inflammatory responses in various types of cells including hepatocytes and hepatic stellate cells. Liver is not only a target organ, but also an important site for clearance and catabolism of circulating AGEs. Although there are several papers to suggest the involvement of AGEs-RAGE system in various types of liver diseases such as non-alcoholic steatohepatitis, liver cirrhosis and cancers, as far as we know, there are few comprehensive reviews to deal with this issue. Therefore, in this paper, we shortly review the pathological role of AGEs and RAGE in various liver diseases.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18473847     DOI: 10.2174/138161208784139701

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  51 in total

Review 1.  Does accumulation of advanced glycation end products contribute to the aging phenotype?

Authors:  Richard D Semba; Emily J Nicklett; Luigi Ferrucci
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2010-05-17       Impact factor: 6.053

2.  Metformin prevents hepatocellular carcinoma development by suppressing hepatic progenitor cell activation in a rat model of cirrhosis.

Authors:  Danielle K DePeralta; Lan Wei; Sarani Ghoshal; Benjamin Schmidt; Gregory Y Lauwers; Michael Lanuti; Raymond T Chung; Kenneth K Tanabe; Bryan C Fuchs
Journal:  Cancer       Date:  2016-02-23       Impact factor: 6.860

3.  Elevation of Serum Levels of Advanced Glycation End Products in Patients With Non-B or Non-C Hepatocellular Carcinoma.

Authors:  Hiromi Kan; Sho-ichi Yamagishi; Ayako Ojima; Kei Fukami; Seiji Ueda; Masayoshi Takeuchi; Hideyuki Hyogo; Hiroshi Aikata; Kazuaki Chayama
Journal:  J Clin Lab Anal       Date:  2014-09-23       Impact factor: 2.352

Review 4.  Contribution of the toxic advanced glycation end-products-receptor axis in nonalcoholic steatohepatitis-related hepatocellular carcinoma.

Authors:  Jun-Ichi Takino; Kentaro Nagamine; Takamitsu Hori; Akiko Sakasai-Sakai; Masayoshi Takeuchi
Journal:  World J Hepatol       Date:  2015-10-18

5.  Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH.

Authors:  Yuki Kimura; Hideyuki Hyogo; Sho-ichi Yamagishi; Masayoshi Takeuchi; Tomokazu Ishitobi; Yoshitaka Nabeshima; Koji Arihiro; Kazuaki Chayama
Journal:  J Gastroenterol       Date:  2010-01-30       Impact factor: 7.527

6.  Small interfering RNA targeting receptor for advanced glycation end products suppresses the generation of proinflammatory cytokines.

Authors:  Xiao-Wei Wang; Wei-Dong Li; Jin-Rong Xia; Zhan Li; Xiao-Gang Cai
Journal:  Exp Ther Med       Date:  2015-06-11       Impact factor: 2.447

7.  Soluble receptor for advanced glycation end products and risk of liver cancer.

Authors:  Kristin A Moy; Li Jiao; Neal D Freedman; Stephanie J Weinstein; Rashmi Sinha; Jarmo Virtamo; Demetrius Albanes; Rachael Z Stolzenberg-Solomon
Journal:  Hepatology       Date:  2013-05-14       Impact factor: 17.425

8.  The ubiquitous conserved glycopeptidase Gcp prevents accumulation of toxic glycated proteins.

Authors:  Chen Katz; Ifat Cohen-Or; Uri Gophna; Eliora Z Ron
Journal:  MBio       Date:  2010-08-24       Impact factor: 7.867

9.  Carbonyl stress phenomena during chronic infection with Opisthorchis felineus.

Authors:  Irina V Saltykova; Ludmilla M Ogorodova; Vladimir V Ivanov; Aleksandr O Bogdanov; Elena A Gereng; Ekaterina A Perina; Paul J Brindley; Alexsey E Sazonov
Journal:  Parasitol Int       Date:  2016-01-08       Impact factor: 2.230

10.  The Correlation Between Obesity-Related Diseases and Non-alcoholic Fatty Liver Disease in Women in the Pre-operative Evaluation for Bariatric Surgery Assessed by Transient Hepatic Elastography.

Authors:  Fernando de Barros; Sérgio Setúbal; José Manoel Martinho; Nathalie Carvalho Leite; Thais Guaraná; Ana Beatriz Soares Monteiro; Cristiane A Villela-Nogueira
Journal:  Obes Surg       Date:  2016-09       Impact factor: 4.129

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.